Introduction
The status epilepticus (SE) is a frequent neurological emergency requiring immediate treatment. SE is defined as a single clinical seizure lasting more than 30 min or repeated seizures over a period of more than 30 min without intervening recovery of consciousness. 1 It may present as convulsive or non-convulsive SE. Clinical symptoms and EEG changes may be generalized, lateralized, or focal. The average incidence of SE is at least 20/100,000 in the western economies. The highest incidence rates could be found in patients older than 60 years and in infants younger than 12 months. 2 Current guidelines recommend the initial use of benzodiazepines, preferably Lorazepam (LZP), followed by Phenytoin (PHT). If SE remains refractory to first-line treatment, the use of barbiturates, Propofol or Midazolam is recommended. 3, 4 Narcotic doses of these medications routinely require patients to receive artificial ventilation and intensive therapy. Therefore, a less aggressive approach may be more beneficial for patients with respiratory or circulatory problems. Valproate (VPA) and Levetiracetam (LEV) are two anticonvulsant drugs that are available as intravenous formulation and are considered as alternative therapeutic options. 5 Lacosamide (LCM) is a novel anticonvulsant agent that has been approved for add-on therapy in patients with partial and secondary generalized seizures by the European drug licensing authority EMEA. 2 Intravenous LCM has biovailability comparable to that of the oral formulation and has been approved for partial and generalized seizures as replacement when oral administration is not possible. LCM as a parenteral solution could potentially be useful for patients who require rapid loading of anticonvulsants, such as SE. We describe seven patients who were successfully treated with Lacosamide intravenously on our neurological intensive care unit with SE resistant to standard first-line therapy.
Results
SE was defined as ongoing automotor or tonic-clonic symptoms, or repetitive seizure without recovery of consciousness in between for at least 30 min, and/or confirmation of an EEG status pattern on routine 10-20 EEG. ''Refractory SE'' was defined as ongoing SE despite adequate first-line treatment with benzodiazepines and/or phenytoin. All patients received brain CT or MRI scans on the day of admission. SE was considered responsive to LCM if EEG status resolved within 24 h after the start of LCM-i.v. and no further antiepileptic agents were added to the treatment protocol during this time period.
Patient one
A 77-year-old male patient with a history of atrial fibrillation, hypertension and diabetes mellitus was admitted to the department of neurosurgery after he had collapsed at home. Intubation and artificial ventilation was started by the emergency physician. Status epilepticus (SE) is a frequent neurological emergency requiring immediate treatment. Therapy usually requires intravenous anticonvulsive medication. Lacosamide is a novel anticonvulsant drug that is available as infusion solution. We describe seven patients with focal SE who were treated with intravenous Lacosamide. All patients in our case series were unsuccessfully treated with other antiepileptic drugs before Lacosamide i.v. was added. In all cases, SE was terminated within 24 h after Lacosamide. There were no serious side effects or adverse events attributable to Lacosamide i.v. Our data suggest that Lacosamide might be an effective add-on treatment, if standard drugs fail or are unsuitable.
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Cranial computed tomography (CCT) showed a large right hemispheric subdural hematoma with a 9 mm midline shift requiring urgent hematoma evacuation and decompressive craniectomy. 24 h after surgery, the patient experienced two right hemispheric focal, tonic-clonic seizures, which were treated by intravenous VPA (1500 mg/d). In the following course the patient remained comatose, despite cessation of clonic symptoms, the EEG showed ongoing right hemispheric electrographic SE. Propofol (2%) was used to suppress epileptiform discharges, however, after discontinuation, focal status reappeared. Since, the patient remained comatose throughout treatment with LEV (2 Â 3 g/d) and Topiramat 2 Â 200 mg/d (TPM) were added, without improving the EEG status pattern. Therefore, 21 days after the first focal seizure, the patient received LCM intravenously (400 mg initial bolus, then 400 mg daily). Electrographic SE resolved within 24 h, when the patient woke up, he suffered from hemiparesis on the left. At least he was sent to a rehabilitation centre.
Patient two
This 63-year-old male patient with a history of ischemic stroke was admitted to our department after he was picked unconsciously by police. His history contained no other medical conditions and no known allergies or illnesses. CCT showed a right hemispheric grain, due to a stroke. The analysis of liquor was normal. The EEG showed right hemispheric status epilepticus. PHT (20 mg/kg/30 min) was used to suppress epileptiform discharges. Because of ongoing SE controlled by continuous EEG monitoring, Propofol (2%) was used 12 h after first application of PHT. In the following course the patient remained comatose and EEG showed right hemispheric status epilepticus after discontinuation of Propofol. 48 h after admission narcosis was continued with Midazolam (0.2 mg/kg/h) and a treatment with LEV (2 Â 2 g/d) was initiated. The EEG control after further 24 h showed ongoing SE that resolved within 24 h after LCM-i.v. (400 mg bolus, 400 mg daily, thereafter). The patient woke up rapidly without a significant neurological deficit.
Patient three
The 80 years old patient with a history of hypertension, COPD and alcohol abuse was admitted to our department after he experienced a first focal, left hemispheric automotor seizure. The emergency team had already administered 10 mg intravenous diazepam during transport. Emergency laboratory tests showed a high serum-concentration of theophyllin. The CCT appeared normal. Continuous EEG monitoring was started approximately 2 h after beginning of the symptoms and initially showed rhythmic slowing and spiking in the left hemisphere.
Administration of a total of 2 g LEV within 24 h (2 Â 2 g/d thereafter) resulted in amplitude reduction, but not in cessation of rhythmic epileptiform activity. The patient remained comatos and Midazolam (0.2 mg/kg/h) was used to suppress epileptiform discharges, however, after discontinuation, focal status reappeared. Therefore, 48 h after the first focal seizure, the patient received TPM (3 Â 50 mg/d) which had no effect. 48 h after the first application of TPM Lacosamid was started intravenously (400 mg bolus, 400 mg daily thereafter). Both, clinically and electroencephalographically focal SE resolved within 24 h thereafter. Because of serve COPD the weaning appeared difficult, when the patient was discharged form our hospital he followed simple challenges but still needed artificial ventilation.
Patient four
The 83 years old female patient with a history of epilepsy, dementia, alcohol abuse and mamma carcinoma was admitted to our department because of a generalized tonic-clonic seizure. Anticonvulsive therapy was LEV (1 g/d) and VPA. Emergency laboratory tests showed a therapeutic serum VPA level. 4 days after admission, the patient experienced a right hemispheric focal, tonic-clonic epileptic seizure, although the therapy with LEV had been exalted (2 Â 3 g/d) since the day of admission. CCT showed a right hemispheric subdural hematoma, which made hematoma evacuation necessary. After neurosurgery the patient remained comatose, EEG showed right hemispheric status epilepticus. Therefore, Propofol (2%) and TPM (2 Â 400 mg/d) were used successfully to suppress epileptiform discharges. 7 days after the application of Propofol and TPM the focal status reappeared, both clinically and electroencephalographically. Therefore, the patient received LCM intravenously (400 mg bolus, 400 mg daily thereafter). Remarkably, both clinically and electroencephalographically focal SE resolved within 24 h thereafter.
Patient five
This 62 years old male patient was admitted to our hospital, because of a large right hemispheric subdural hematoma, which needed urgent hematoma evacuation and decompressive craniectomy. Immediately after surgery, the patient experienced a right hemispheric tonic-clonic seizure, which was treated by intravenous VPA (3 Â 900 mg/d). In the following 2 h the patient remained comatose, despite cessation of clonic symptoms, the EEG showed ongoing right hemispheric and for short times generalized electrographic SE, which were treated by intravenous LEV (2 Â 2 g). Moreover, Propofol (2%) was used to suppress epileptiform discharges. 24 h later Propofol was discontinuated and focal status reappeared. Therefore, the patient received LCM intravenously (400 mg bolus, 400 mg daily thereafter). Both, clinically and electroencephalographically focal SE, resolved within 24 h thereafter. The patient woke up rapidly without a significant neurological deficit.
Patient six
This 61 years old male patient was admitted to our department because of a right hemispheric focal status epilepticus. He had a history of diabetes mellitus and hepatic transplantation after alcoholic cirrhosis (Child B) in 2009.
After an intracerebral bleeding in 2009 he experienced one focal epileptic seizure, therefore he takes a medication with LEV (1 g/d). This effective anticonvulsive medication has been discontinuated because of increasing transaminase enzymes, just before the admission to our hospital. Administration of a total of 2 g LEV within 24 h and 2 Â 1 g/d thereafter did not resulted in cessation of clinically status epileptius and rhythmic epileptiform activity. For that reason the patient received a bolus of 400 mg LCM and both, clinically and electroencephalographically focal SE, resolved within 1 h thereafter.
Patient seven
The 33 years old male patient with a history of symptomatic epilepsy due to an infantile brain damage was admitted to our department because of a generalized epileptic seizure. The patient had a premedication with Phenobarbital (3 Â 75 mg/d). The emergency physician started artificial ventilation and a therapy with Midazolam (0.2 mg/kg/h). The following EEG showed burst suppression pattern. After administration of a total of 2 g LEV and 2 Â 1 g/d thereafter the therapy with Midazolam was discontinuated and the EEG showed delta wave activity. 4 days thereafter, focal right hemispheric SE reappeared clinically and detected by EEG. Although the therapy with LEV was exalted (3 g/d) and SE was suppressed the patient experienced a further right hemispheric SE one week thereafter. For that reason the patient received LCM intravenously (400 mg bolus, 400 mg daily thereafter) and both clinically and electroencephalographically focal SE resolved within 24 h thereafter.
Discussion
Status epilepticus is a neurological emergency that requires rapid i.v. anticonvulsant treatment. However, only few of the available drugs are explicitly licensed for treatment of status epilepticus, and most of them such as PHT or thiopental carry a high risk of adverse events or require artificial ventilation, or both. 2 Previous reports have suggested that intravenous LEV and VPA are effective and well tolerated as treatment for SE. [6] [7] [8] All patients in our case series were treated with either LEV or VPA (or both) in combination with TPM, benzodiazepines and Propofol, without control of clinical or electrographic SE. In all cases, SE was terminated within 24 h after application of LCM i.v. As all patients were simultaneously treated with other antiepileptic drugs (AEDs), termination of SE is most likely attributable to additional effects of LCM to its co-medications. To our knowledge until now there are only few case reports which describe a possible effectiveness of LCM in focal SE. 9, 10 In our cases no side effects or interactions occurred which were attributable to LCM. There were no significant changes in heart rate or blood pressure. No increase of catecholamine dose was required and no cardiac arrhythmias were noted. Our data shows that LCM might be an effective add-on treatment, if standard drugs fail or are unsuitable. Intravenous LCM is easy to handle, and has the same safety profile as its oral formulation. However, prospective and controlled trials are needed to assess the efficacy and safety in particular in longterm application of LCM for this indication.
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